Home  |  Contact

Cellosaurus 7.159.2 (CVCL_B0L4)

[Text version]
Cell line name 7.159.2
Synonyms 50-002-7.159.2 HSFM; MEDI-573
Accession CVCL_B0L4
Resource Identification Initiative To cite this cell line use: 7.159.2 (RRID:CVCL_B0L4)
Comments Group: Patented cell line.
Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7424.
Biotechnology: The monoclonal antibody produced by this hybridoma is tested as a potential therapeutic antibody with antineoplastic activity under the name dusigitumab.
Monoclonal antibody isotype: IgG2, lambda.
Monoclonal antibody target: UniProtKB; P05019; Human IGF1.
Monoclonal antibody target: UniProtKB; P01344; Human IGF2.
Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin.
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy Parent: CVCL_4032 (P3X63Ag8.653)
Category Hybridoma
Publications

PubMed=21245093; DOI=10.1158/0008-5472.CAN-10-2274
Gao J., Chesebrough J.W., Cartlidge S.A., Ricketts S.-A., Incognito L.S., Veldman-Jones M., Blakey D.C., Tabrizi M., Jallal B., Trail P.A., Coats S., Bosslet K., Chang Y.S.
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Cancer Res. 71:1029-1040(2011)

Patent=US9796779
Raeber O., Gazit-Bornstein G., Yang X.-D., Cartlidge S.A., Tonge D.W.
Binding proteins specific for insulin-like growth factors and uses thereof.
Patent number US9796779, 24-Oct-2017

Cross-references
Cell line collections (Providers) ATCC; PTA-7424
Biological sample resources ABCD; ABCD_AA677
Encyclopedic resources Wikidata; Q108819731
Entry history
Entry creation23-Sep-2021
Last entry update30-Jan-2024
Version number5